ProteinLogic wins Med Tech award at NHS Healthcare Innovation Expo 2013

CAMBRIDGE, UK (2013-03-25) – ProteinLogic, the biomarker discovery and exploitation company, was judged to have presented the strongest proposal in the Med Tech category to the Innovators’ Den at the NHS Healthcare Innovation Expo 2013 in London on March 14th.

ProteinLogic’s Chairman Dr Paul Rodgers presented the winning pitch to a panel including leading venture capitalists and senior NHS decision makers in front of a live audience. He outlined the ProteinLogic technology and its progress in implementing a business strategy to commercialise biomarker-based diagnostic tests for a range of diseases including tuberculosis and hepatitis B.

Eighty companies entered the competition and five were selected to present at the Innovators’ Den in each of three categories: Digital Innovations, Med Tech and Service Challenges. The competition was organised by the Technology Strategy Board and Capita.

Dr Rodgers said: “We are delighted with the recognition of ProteinLogic’s innovative technology and its business proposition provided by the distinguished panel of investors and NHS decision makers. We thank the Technology Strategy Board for giving us the opportunity to participate in the Innovators’ Den.”


Further information:

Dr Paul Rodgers, ProteinLogic Ltd, telephone: +44 (0)1223 703146


ProteinLogic is a biomarker discovery and exploitation company developing a novel diagnostic platform and diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The Company has developed a proprietary biomarker technology (ImmiPrint®) with potential to diagnose and predict early onset of diseases, and to provide information as to how a disease is likely to develop and respond to particular drug treatments. The technology is based upon the profiling of a discrete subset of immune system proteins (‘sCD’) found in the blood and other body fluids.

In addition to the TB and hepatitis B diagnostic tests there are a number of potential follow-on products in the Company’s pipeline.